These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24024474)

  • 1. Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
    Scortechini I; Montanari M; Mancini G; Inglese E; Calandrelli M; Chiarucci M; Offidani M; Capelli D; Gini G; Poloni A; Mancini S; Raggetti G; Leoni P; Olivieri A
    Leuk Lymphoma; 2014 Jul; 55(7):1657-60. PubMed ID: 24024474
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
    Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
    Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
    Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
    Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
    Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
    Phillips GL; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1033-42. PubMed ID: 21074630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
    Przepiorka D; van Besien K; Khouri I; Hagemeister F; Samuels B; Folloder J; Ueno NT; Molldrem J; Mehra R; Körbling M; Giralt S; Gajewski J; Donato M; Cleary K; Claxton D; Braunschweig I; Andersson B; Anderlini P; Champlin R
    Ann Oncol; 1999 May; 10(5):527-32. PubMed ID: 10416001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
    Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
    Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
    Au WY; Lie AK; Siu LL; Chan EC; Ooi GC; Leung AY; Liang R; Kwong YL
    Ann Hematol; 2003 Sep; 82(9):548-51. PubMed ID: 14504811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
    Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
    Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
    Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
    Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE
    Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
    Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
    Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
    Marchesi F; Capria S; Pedata M; Terrenato I; Ballotta L; Riccardi C; Papa E; Riemma C; Trisolini S; Celentano M; Regazzo G; Ferrara F; Mengarelli A; Picardi A
    Leuk Lymphoma; 2020 Sep; 61(9):2238-2241. PubMed ID: 32419550
    [No Abstract]   [Full Text] [Related]  

  • 19. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
    Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS
    Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
    Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.